Due to health issues, this site is no longer maintained and will be shut down shortly. |
Cingulate Inc., a clinical stage biopharmaceutical company, focuses on the development of product candidates for the treatment of central nervous system and neurobiological disorders. The company' lead product candidates are CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine) for the treatment of attention deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
$1.03 +0.01 (0.98%)
As of 03/24/2023 16:00:01 EST IEX book CBOE book
2022 © Stock Market MBA, Inc.